Infinite Epigenetics acquired Tally Health, expanding its platform to cover epigenetic diagnostics, adult DNA methylation datasets, and personalized interventions focused on improving healthspan. The acquisition builds on the use of methylation signals for lifestyle or intervention stratification. For healthcare innovation teams, the deal positions Infinite as a more end-to-end player spanning testing, datasets, and intervention tools. The combined capabilities could support studies that connect methylation patterns to longer-term outcomes. No transaction terms were included in the excerpt, but the move underscores ongoing consolidation in consumer-adjacent and clinical-adjacent epigenetics.